177Lu-FAP-VG-02 / Vitsgen Therapeutics - LARVOL DELTA

[177Lu]Lu-VG-FAP-01, a Novel Cyclic Radiopeptide Targeting Fibroblast Activation Protein alpha (FAP) (SNMMI 2025) - "[177Lu]Lu-VG-FAP-compounds’ imaging data illustrated structure and activity relationships (SARs). Among them, [177Lu]Lu-VG-FAP-01 was a superior analogue with higher tumor uptake and longer retention. In vivo imaging study, comparatively, [177Lu]Lu-VG-FAP-01 (4.02% ID/g at 4 h p.i.; 2.51% ID/g at 24 h p.i.; 2.10% ID/g at 72 h p.i.) had 17 fold increase in tumor uptake at 4 hr post injection (p.i.) and 14 fold more uptakes at 24 hr p.i. than clinical candidate [177Lu]Lu FAP-2286 (0.23% ID/g at 4 h p.i.; 0.18% ID/g at 24 h p.i.)."

Oncology • Solid Tumor • CAFs • FAP

[177Lu]Lu-VG-FAP-01, a Novel Cyclic Radiopeptide Targeting Fibroblast Activation Protein alpha (FAP) (SNMMI 2025) - "[177Lu]Lu-VG-FAP-compounds’ imaging data illustrated structure and activity relationships (SARs). Among them, [177Lu]Lu-VG-FAP-01 was a superior analogue with higher tumor uptake and longer retention. In vivo imaging study, comparatively, [177Lu]Lu-VG-FAP-01 (4.02% ID/g at 4 h p.i.; 2.51% ID/g at 24 h p.i.; 2.10% ID/g at 72 h p.i.) had 17 fold increase in tumor uptake at 4 hr post injection (p.i.) and 14 fold more uptakes at 24 hr p.i. than clinical candidate [177Lu]Lu FAP-2286 (0.23% ID/g at 4 h p.i.; 0.18% ID/g at 24 h p.i.)."

Oncology • Solid Tumor • CAFs • FAP